About US
Contact us
-
AstraZeneca rides high on sales rebound after cancer drugs, China once again pull throughIt's confirmed: AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to cancer drugs Tagrisso and Lynparza—and once again, China. The British drugmake2019/2/18
-
Staggering under load of talc litigation, J&J supplier Imerys America seeks shelter in bankruptcyFacing “historic” liabilities from thousands of lawsuits claiming its products caused cancer, Johnson & Johnson talc supplier Imerys Talc America and two associated companies filed for bankruptcy2019/2/15
-
Teva forecasts worse-than-expected ‘trough year’ as generics hammer MS drug CopaxoneShares of Teva fell nearly 12% in pre-market trading to $16.80 after the company’s executives conceded during the fourth-quarter earnings report that 2019 would be an even tougher year than analysts h2019/2/15
-
FDA panel supports Janssen’s esketamine nasal spray for depressionJanssen Pharmaceutical has secured recommendation from the US Food and Drug Administration (FDA) advisory committees for the approval of its esketamine nasal spray Spravato to treat adults with treatm2019/2/14
-
EC expands Takeda’s Adcetris authorisation for Hodgkin lymphomaThe European Commission (EC) has expanded the marketing authorisation of Takeda Pharmaceutical’s Adcetris (brentuximab vedotin) to adults with previously untreated CD30+ Stage IV Hodgkin lymphoma. Th2019/2/14
-
Novartis to divest Proleukin’s US rights to Clinigen for $210mNovartis has signed an agreement to divest the US rights to its Proleukin (aldesleukin) medicine to UK-based Clinigen Group for a total cash consideration of up to $210m. The transaction involves an2019/2/13
-
FDA grants Merck’s Keytruda priority review as first line therapy for HNSCCMerck has announced the US Food and Drug Administration (FDA) has granted priority review for its supplementary biologics license application (sBLA) for Keytruda as first line treatment for patients w2019/2/13
-
Samsung Bioepis forms new alliance to expand in ChinaSamsung Bioepis has signed a licensing deal with healthcare-focused private equity firm C-Bridge Capital to accelerate expansion in mainland China. The agreement involves the biopharmaceutical compan2019/2/12
-
Regeneron and Sanofi cut US list price of PraluentRegeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%. The price for the drug will be lowered to $5,850 an2019/2/12
-
Mylan’s generic version of asthma drug Advair receives FDA approvalThe US Food and Drug Administration (FDA) has approved Mylan’s generic version of GlaxoSmithKline’s (GSK) asthma treatment Advair Diskus (fluticasone propionate and salmeterol inhalation powder). Dub2019/2/3